References
Spencer C, et al. Drugs Aging 3: 556–584, 1993
Henwood JM, Todd PA. Drugs 36: 11–31, 1988
Rolandi E, et al. J Cardiovasc Pharmacol 14 (Suppl. 8): 93–103, 1989
Riva E, et al. Int J Clin Pharmacol Res 9: 21–28, 1989
Dei Cas L, et al. J Cardiovasc Pharmacol 14 (Suppl. 8): 111–117, 1989
Dalla Volta S, et al. Am J Noninvas Cardiol 5 (Suppl. 1): 15–17, 1991
Simpson FO. In Speight TM (ed.) Avery’s drug treatment, 3rd ed., pp. 676–731, Adis Press, Auckland, 1987
British National Formulary 27: 53–82, 1994
Cavalli A, et al. Int J Cardiol 22: 381–387, 1989
Kleber FX, Thyroff-Freisinger U. Cardiology 77 (Suppl. 5): 75–80, 1990
van Veldhuisen DJ, et al. J Am Coll Cardiol 21: 378A, 1993
Sher D, et al. Arzneim Forsch 41: 402–409, 1991
Hampton JR, Cowley AJ. Eur Heart J 12 (Suppl. C): 42–45, 1991
Ghiringelli S, et al. Curr Ther Res 48: 96–111, 1990
Terrachini V, et al. Curr Ther Res 50: 753–761, 1991
Kleber FX, Thyroff-Freisinger U. Cardiology 77 (Suppl. 5): 67–74, 1990
Abbondati G, et al. Cardiovasc Drugs Ther 3: 897–902, 1989
Rights and permissions
About this article
Cite this article
Ibopamine: suitable as add-on therapy in CHF. Drugs Ther. Perspect 4, 5–7 (1994). https://doi.org/10.2165/00042310-199404050-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199404050-00002